The Rx Research Corner is a blog written by the Research Team at PCMA. This blog will take a closer look at complex data and new research findings. Topics cover the PBM and prescription drug space and range from pricing, to policies, and to patient issues such as access and equity.
High spending on prescription drugs with both orphan and non-orphan indications suggest potential misuse of Orphan Drug Act designations.
Using a gold-standard pharmacy dataset from the National Council for Prescription Drug Programs (NCPDP) and a transparent methodology, PCMA produces credible research with a clear conclusion: there are more independent pharmacies now than any time over the last decade.
Paying pharmacies more for dispensing medications will raise prescription drug costs without improving value.
Continuing the theme from our previous blog on the benefits of competition among prescription drugs, we now turn to another type of competition: the role of biosimilars in lowering the escalating prices of biologic drugs.
In a previous blog post, I talked about one tactic (patent thickets) that drug manufacturers use to keep direct competitor products – generics and biosimilars – off the market. On the other side of that coin: What happens to drug costs when direct competitor products enter the market?
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
May is Asthma Awareness Month, and today – May 5 – is World Asthma Day. The Asthma and Allergy Foundation of America is marking the day with the release of their 2021 Asthma Capitals Report.
According to a new analysis, there are now 70 PBMs operating in a diverse and competitive marketplace.
